Efficacy of addition of HB vaccine in patients with chronic hepatitis B who are still HBeAg-positive after one year of entecavir administration: a randomized controlled trial
Not Applicable
- Conditions
- HBeAg-positive chronic hepatitis B
- Registration Number
- JPRN-UMIN000001627
- Lead Sponsor
- Osaka City University Graduate School of Medicine
- Brief Summary
The present study showed that HB vaccine therapy did not have anti-HBV effect for patients with entecavir poor response.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.use of lamivudine or any other nucleos(t)ide analogues for hepatitis B 2.use of immunosuppressive or immunomodulatory drugs 3.presence of HCV infection and other likely causes of chronic liver disease 4.clinical signs of decompensated cirrhosis or liver failure 5.severe complication (poor renal, cardiac, or respiratory function) 6.women who are possibly pregnant, expectant mothers, and lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method